Most of the UFO sightings occurred around 8:15-9:00 PM, while the flairs were known to be ignited around 10:00 - 10:30 PM. Really bizarre fact about the Phoenix lights, the Governor of Arizona at that time has admitted…
Again want to say I really appreciate how thoughtful you are about this. I just want to offer a few of my thoughts because you've been so generous with yours. So you know, I work in the industry. More on the biz side…
This is helpful. Let me ask a question. Why do you think that cheaper development costs will ultimately lead to lower drug prices? I think we would both agree that drugs are not priced based on cost. Even if R&D were…
First, really appreciate the engagement here. This is a hugely important problem and this interview and your presentation of it is a great contribution. I think one of the things that gets lost when we talk about…
I think we're saying the same thing. The disease model itself is necessarily limited. Sure you have a molecule that hits the target, great. But the struggle comes from being able to get that molecule to target in vivo…
Could you expand a bit on that? I'm having a hard time making the connection between declining efficiency and there necessarily being something broken about the science. To expand just a bit: Scannell seems to be…
Most of the UFO sightings occurred around 8:15-9:00 PM, while the flairs were known to be ignited around 10:00 - 10:30 PM. Really bizarre fact about the Phoenix lights, the Governor of Arizona at that time has admitted…
Again want to say I really appreciate how thoughtful you are about this. I just want to offer a few of my thoughts because you've been so generous with yours. So you know, I work in the industry. More on the biz side…
This is helpful. Let me ask a question. Why do you think that cheaper development costs will ultimately lead to lower drug prices? I think we would both agree that drugs are not priced based on cost. Even if R&D were…
First, really appreciate the engagement here. This is a hugely important problem and this interview and your presentation of it is a great contribution. I think one of the things that gets lost when we talk about…
I think we're saying the same thing. The disease model itself is necessarily limited. Sure you have a molecule that hits the target, great. But the struggle comes from being able to get that molecule to target in vivo…
Could you expand a bit on that? I'm having a hard time making the connection between declining efficiency and there necessarily being something broken about the science. To expand just a bit: Scannell seems to be…